Prognostic impact and risk factors of cancer‐associated thrombosis events in stage‐IV cancer patients treated with immune checkpoint inhibitors

Venous thromboembolism (VTE) incidence and risk factors in patients (pts) with non-small cell lung cancer (NSCLC) receiving front-line therapy.

(2020) Jai Narendra Patel et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune-related adverse events of checkpoint inhibitors

(2020) Manuel Ramos-Casals et al.   Nature Reviews Disease Primers

A decade of immune-checkpoint inhibitors in cancer therapy

(2020) Caroline Robert   Nature Communications

Incidence, risk factors and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy

(2020) Florian Moik et al.   BLOOD

Clinically significant bleeding with immune checkpoint inhibitors: A retrospective cohort study

(2020) Tariq Kewan et al.   EUROPEAN JOURNAL OF CANCER

Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review

(2020) Cinzia Solinas et al.   THROMBOSIS RESEARCH

Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors

(2019) Yosuke Ando et al.   INVESTIGATIONAL NEW DRUGS

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

(2015) J. Naidoo et al.   ANNALS OF ONCOLOGY

Epidemiology and pathophysiology of cancer-associated thrombosis

(2010) S Noble et al.   BRITISH JOURNAL OF CANCER

High prevalence and risk factors of thromboembolism in stage IV melanoma

(2010) A Sparsa et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Development and validation of a predictive model for chemotherapy-associated thrombosis

(2008) A. A. Khorana et al.   BLOOD

Cancer-Associated Thrombosis: Prevention and Treatment

(2008) Kelsey Brose   Current Oncology